# Investigating Resistance and Resilience Mechanisms in Alzheimer’s Disease

> **NIH NIH R01** · MAYO CLINIC ROCHESTER · 2024 · $779,639

## Abstract

PROJECT SUMMARY / ABSTRACT
Cognitive Aging and risk of Alzheimer's disease, and Alzheimer's related dementias (AD/ADRD) is due to
multiple aging and pathological processes that are driven by several upstream brain mechanisms and risk
factors. The success of recent multi-domain interventions and our preliminary data suggests that multiple
mechanisms need to be targeted for effective dementia prevention. In 2018, we proposed a simplistic conceptual
framework that builds on existing concepts using the nomenclature of resistance in the context of avoiding AD
pathology and resilience in the context of coping with AD pathology for investigating these distinct mechanisms.
This proposal addresses an important barrier for developing effective therapeutic or preventive strategies for AD
dementia - the poor understanding of how upstream risk factors and brain mechanisms (resistance and
resilience) that could contribute to or protect from protein accumulation and neurodegeneration. Our central
hypothesis is that identifying upstream brain mechanisms of resistance and resilience and modeling the complex
inter-relationships between protective factors, brain mechanisms, and longitudinal changes in amyloid, tau, and
cognition will aid in effective design of dementia prevention strategies.
To test this hypothesis, our primary aim is to identify mechanisms of resistance and resilience using the existing
infrastructure of the population-based Mayo Clinic Study of Aging (MCSA) (individuals aged ≥50 years) and
Rochester Epidemiology Project (REP) which maintains a comprehensive medical records-linkage system. We
will collect the following variables for this proposal: Genetics, Social Determinants of Health (SDoH), and
systemic health (up to 20 years prior to scan from REP), longitudinal PiB and tau PET, baseline cutting edge
MRI (high resolution T1/T2/FLAIR and multi-shell diffusion MRI to assess perivascular spaces, microstructural
integrity, and cortical thickness), and cognitive decline. Our secondary aim is to develop and validate MRI-
based resilience markers that can be used in the NIA-AA research framework alongside with AT(N) biomarkers
to adjust for individual variability in cognition. Considering brain health measures (other than those included in
the evaluation of N) as resilience markers will improve the prediction of cognitive decline across all aging and
dementia studies. These measures will be able to capture biological variability due to SDoH and systemic health
and facilitate better comparison of biomarkers across populations.

## Key facts

- **NIH application ID:** 10788398
- **Project number:** 5R01AG056366-07
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** PRASHANTHI VEMURI
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $779,639
- **Award type:** 5
- **Project period:** 2017-09-15 → 2028-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10788398

## Citation

> US National Institutes of Health, RePORTER application 10788398, Investigating Resistance and Resilience Mechanisms in Alzheimer’s Disease (5R01AG056366-07). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10788398. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*